Biotech Values

[jbog]

JQ1234

The company’s newest product, the bone drug denosumab, is sold under the brand names Prolia and Xgeva. Sales of the product, which have been considered key to Amgen’s future growth, were $28 million.

Prolia was approved last year for the treatment of osteoporosis, while Xgeva was approved Nov. 18 by the U.S. Food and Drug Administration.

Xgeva is used for the prevention of fractures in certain patients with cancer that has spread to the bones.

Being that Prolia for Osteoporosis is dosed semi-annually it seems that sales are really lacking considering it has been marketed for 6 months now.